Heparin, a widely available and low-cost drug, can help in limiting lung damage when inhaled by COVID-19 patients, researchers from the Australian National University (ANU) have found. The study's lead Professor Frank van Haren confirmed initial results of the trials indicate "heparin is safe and effective" against COVID-19. He also believes it can be "a possible preventative against the virus".